What’s Next: The Landscape of Innovation in 2019 and Beyond

3:00 PM - 4:30 PM, Monday, June 3,2019 ・ 103ABC, Level 100
As companies face the need to discover or acquire future drivers of value, R&D is both challenging and costly, with over $165 B spent globally in 2017 alone. In this session, we will highlight emerging clusters of innovation attracting capital and the key therapeutic targets and novel mechanistic approaches with the potential to drive value creation in the future. We will also examine how market forces and overall value in therapeutic areas may drive investment decisions in R&D and M&A, both today and into the future. Join us for a forward-looking discussion of what’s next for R&D in the global pharmaceutical industry, highlighting noteworthy differences in disease areas of focus and therapeutic targets relevant for companies of all sizes. We will share perspectives on geographic considerations including regions serving as hotbeds of innovative activity and seek to identify the drivers that will shape future areas of value within the pharmaceutical industry. Sponsored by: ClearView Healthcare Partners
Moderator
photo
Senior Vice President & Head, MRL Business Development & Licensing
Merck & Co., Inc.
Speakers
photo
Co-founder, CEO and Director
Axial Biotherapeutics
photo
Vice President, Industry Research
Biotechnology Innovation Organization
photo
Senior Vice President & Head, MRL Business Development & Licensing
Merck & Co., Inc.
photo
Managing Director
ClearView Healthcare Partners
photo
Vice President, Worldwide Business Development
Pfizer Inc.
photo
Chairman and CEO
Xontogeny, LLC
photo
Chief Financial Officer and Chief Business Officer
Senti Biosciences, Inc.